MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data

Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2020-10-19
Last Posted Date
2023-07-27
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
220518
Registration Number
NCT04593030
Locations
🇺🇸

Brigham And Women's Hospital, Boston, Massachusetts, United States

Replication of the RELY Anticoagulant Trial in Healthcare Claims Data

Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2020-10-19
Last Posted Date
2023-07-27
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
78140
Registration Number
NCT04593043
Locations
🇺🇸

Brigham And Women's Hospital, Boston, Massachusetts, United States

Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data

Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2020-10-19
Last Posted Date
2023-07-28
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
102636
Registration Number
NCT04593056
Locations
🇺🇸

Brigham And Women's Hospital, Boston, Massachusetts, United States

Rivaroxaban vs. Warfarin in CVT Treatment

Phase 3
Completed
Conditions
Cerebral Vein Thrombosis
Interventions
First Posted Date
2020-09-29
Last Posted Date
2023-02-16
Lead Sponsor
Damascus University
Target Recruit Count
71
Registration Number
NCT04569279
Locations
🇸🇾

Damascus University, Damascus, Damascus Governorate, Syrian Arab Republic

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2020-08-11
Last Posted Date
2022-06-15
Lead Sponsor
Bayer
Target Recruit Count
116049
Registration Number
NCT04509193
Locations
🇺🇸

US Optum De-Identified EHR data, Whippany, New Jersey, United States

Gene-guided Warfarin for Anticoagulation Therapy

Not Applicable
Withdrawn
Conditions
Stroke
Interventions
Device: Gene detection (CYP2C9*3, VKORC1)
First Posted Date
2020-07-23
Last Posted Date
2021-08-25
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Registration Number
NCT04482842

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Completed
Conditions
Uterine Hemorrhage
Interventions
Drug: Direct oral anticoagulant (DOACs)
First Posted Date
2020-05-19
Last Posted Date
2025-04-27
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
961985
Registration Number
NCT04394234
Locations
🇺🇸

Janssen R&D, Titusville, New Jersey, United States

The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial

Phase 3
Recruiting
Conditions
Bleeding Post Cardiac Surgery
Indication for Anticoagulation
Interventions
Drug: DOAC
First Posted Date
2020-02-26
Last Posted Date
2025-03-30
Lead Sponsor
Population Health Research Institute
Target Recruit Count
3500
Registration Number
NCT04284839
Locations
🇦🇺

St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia

🇦🇺

Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia

🇨🇦

University of Alberta Hospital, Edmonton, Alberta, Canada

and more 13 locations

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2020-01-31
Last Posted Date
2024-08-01
Lead Sponsor
Bayer
Target Recruit Count
134897
Registration Number
NCT04249401
Locations
🇸🇪

Many locations, Multiple Locations, Sweden

Warfarin Initiation in Mechanical Mitral Valve Replacement Patients

First Posted Date
2020-01-22
Last Posted Date
2020-01-27
Lead Sponsor
Sarah Sabry Hashem
Target Recruit Count
50
Registration Number
NCT04235569
Locations
🇪🇬

The Cardiovascular Hospital, Heliopolis, Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath